The global arteriovenous fistula (AVF) treatment market is projected to reach approximately USD 868.8 million in 2025 and ...

We record a case of pulmonary arteriovenous fistula presenting in a dramatic and unusual way. These lesions are generally diagnosed clinically by consideration of their associated features. In this ...

Background: Arteriovenous fistulae (AVF) are the preferred surgical procedure for vascular access. However, 60% of AVF fail within one year due to aggressive neointimal hyperplasia, which ...

Transvenous access is a necessary tool for numerous cerebrovascular pathologies. Transvenous access in the arm offers several benefits compared with transfemoral access, including patient comfort, the ...

Two cases of pulmonary arteriovenous fistulas with hemiparesis and other neurologic findings, possibly from paradoxical embolization, are described. ... Prager R, Laws K and Bender H (1983) ...

Myelopathy from intracranial dural arteriovenous fistula. G P Kalamangalam 1, J Bhattacharya 2, E Teasdale 2, M Thomas 1; 1 Department of Neurology, Institute of Neurological Sciences, Southern ...

Background The development of de novo dural arteriovenous fistula(s) following endovascular embolization of a prior high-flow pial arteriovenous fistula (PAVF) has not previously been reported and the ...

Percutaneous Arteriovenous Fistula Creation. 2 products. Percutaneous Transmural Arterial Bypass (SFA/Popliteal Treatment) 3 products. Peritoneal Dialysis Implantation Kits. 8 products. Powered Bone ...

(Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced today that the results from its V007 ...

DISCUSSION. In 1964, TGA gained notoriety with the work of Fisher and Adams 5, despite having been previously described by Bender 6 and independently by Guyotat and Courjon 7 in 1956. Only in 1990, a ...

An arteriovenous fistula (AVF) can be defined as an abnormal and permanent communication between an artery and a vein. They may be congenital or acquired, with the latter type being more common.

However, the company is exiting the fistula creation market after 4 years of investment in its development, supporting the Ellipsys platform. Moeller spoke on the challenges of “changing a 50-year-old ...